N | No. Events | Median Years | HR | 95 % CI for HR | HR p-value | |
---|---|---|---|---|---|---|
Race | ||||||
Non-White | 9 | 9 | 1.77 | |||
White | 57 | 57 | 1.93 | 1.20 | (0.57, 2.54) | 0.64 |
Gleason score | ||||||
5–7 | 13 | 13 | 3.59 | |||
8–10 | 51 | 51 | 1.60 | 1.77 | (0.94, 3.34) | 0.08 |
Performance Status | ||||||
0 | 31 | 31 | 1.97 | |||
1–2 | 35 | 35 | 1.70 | 1.20 | (0.74, 1.96) | 0.46 |
Metastatic Volume | ||||||
Low | 31 | 31 | 3.53 | |||
High | 35 | 35 | 1.27 | 2.93 | (1.70, 5.05) | <0.001 |
Treatment | ||||||
ADT | 34 | 34 | 1.60 | |||
ADT + Chemo | 31 | 31 | 2.29 | 0.99 | (0.60, 1.61) | 0.95 |
Diabetes | ||||||
No | 62 | 62 | 1.93 | |||
Yes | 4 | 4 | 0.92 | 2.28 | (0.80, 6.45) | 0.12 |
Age | 66 | 66 | 1.77 | 0.99 | (0.96, 1.02) | 0.67 |
PSA (ln) | 66 | 66 | 1.77 | 1.00 | (0.99, 1.01) | 0.65 |
Insulin (ln) | 66 | 66 | 1.77 | 0.81 | (0.67, 0.98) | 0.03 |
RANK (ln) | 66 | 66 | 1.77 | 0.82 | (0.60, 1.12) | 0.22 |
IGFBP3 (ln) | 66 | 66 | 1.77 | 0.89 | (0.52, 1.51) | 0.66 |
IGFBP1 (ln) | 66 | 66 | 1.77 | 1.05 | (0.87, 1.27) | 0.59 |
IGF I | 66 | 66 | 1.77 | 0.85 | (0.42, 1.74) | 0.66 |
IGF II | 66 | 66 | 1.77 | 0.80 | (0.27, 2.42) | 0.70 |
HGF (ln) | 66 | 66 | 1.77 | 1.63 | (1.06, 2.51) | 0.03 |
OPN | 66 | 66 | 1.77 | 1.56 | (1.13, 2.15) | 0.01 |
C-peptide (ln) | 66 | 66 | 1.77 | 0.62 | (0.39, 1.00) | 0.05 |
PD1 (ln) | 66 | 66 | 1.77 | 0.82 | (0.53, 1.25) | 0.35 |
IL6 (ln) | 66 | 66 | 1.77 | 1.26 | (0.91, 1.75) | 0.17 |
OPG (ln) | 66 | 66 | 1.77 | 0.97 | (0.84, 1.11) | 0.63 |